Heng Sun
Sar, 999078, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
A miniaturized-tumor culture platform for developing anti-tumor immunotherapies.
Journal: Theranostics
Published: January 26, 2026
Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling.
Journal: Biomedicines
Published: September 18, 2025
Lars2-signaling mediates platinum resistance by accumulating cancer stem cell population and suppressing anti-tumor immunity.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: August 11, 2025
RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.
Journal: Cell death & disease
Published: May 10, 2025
Proteasomes suppress anticancer drug-induced cytotoxicity by inhibiting mitochondrial protein import and promoting ROS-BNIP3-mediated mitophagy.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: April 08, 2025
Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer.
Journal: Cell reports. Medicine
Published: December 13, 2024
Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation.
Journal: Pharmacological research
Published: April 30, 2023
MEAI: an artificial intelligence platform for predicting distant and lymph node metastases directly from primary breast cancer.
Journal: Journal of cancer research and clinical oncology
Published: March 21, 2023
Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling.
Journal: Science advances
Published: January 20, 2023
Editorial: Epigenetics of metabolism, immunology and aging.
Journal: Frontiers in genetics
Published: January 02, 2023
Last Updated: 09/26/2026